We revealed that the memory‐enhancing effect of EE intervention in AD could be mediated by (1) alleviation of AD‐related neuropathology, (2) regulation of synapse‐ and neurotransmitter‐associated proteomes, and (3) modulation of neurotransmitters, such as Ach, 5‐HT, and polyamines, in the AD brain. Here, FGFR3 is linked to Alzheimer disease.